Literature DB >> 8145785

Aspirin as an antiplatelet drug.

C Patrono1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145785     DOI: 10.1056/NEJM199405053301808

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  122 in total

1.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 3.  Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

Authors:  C Patrono; P Patrignani; L A García Rodríguez
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 4.  COX in a crystal ball: current status and future promise of prostaglandin research.

Authors:  G A FitzGerald; P Loll
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

5.  Giving aspirin and ibuprofen after myocardial infarction.

Authors:  Stephen E Kimmel; Brian L Strom
Journal:  BMJ       Date:  2003-12-06

Review 6.  Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.

Authors:  Carlo Patrono
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

Review 7.  Management of acute myocardial infarction in the elderly.

Authors:  D E Forman; M W Rich
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

8.  The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils.

Authors:  M L Taylor; M K Ilton; N L Misso; D N Watkins; J Hung; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Treatment recommendations to prevent myocardial ischemia and infarction in patients undergoing vascular surgery.

Authors:  Willem-Jan Flu; Sanne E Hoeks; Jan-Peter van Kuijk; Jeroen J Bax; Don Poldermans
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

10.  Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.

Authors:  Gunnar Fager; Marie Cullberg; Maria Eriksson-Lepkowska; Lars Frison; Ulf G Eriksson
Journal:  Eur J Clin Pharmacol       Date:  2003-07-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.